Biohaven Ltd. (BHVN)
- Insider Monkey
Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In?
We recently compiled a list of the 10 Best GLP-1 and Weight Loss Stocks to Buy Now. In this article, we are going to take a look at where Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) stands against the other GLP-1 and weight loss stocks. According to WHO, more than one billion people worldwide are obese, including […]
- PR Newswire
Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a review of recent accomplishments and anticipated upcoming developments.
- PR Newswire
Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies, provides an overview of its development and regulatory advances across multiple therapeutic areas, and highlights the progress of its innovative degrader pipeline at the Company's 2024 Investor R&D Day today, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. Members of Biohaven's
